Health tech company Aetion on Nov. 1 announced a new tool aimed at bolstering real-world evidence use for small and mid-sized companies.
According to a press release, the tool was co-developed with IBM Watson Health.
“Historically, substantial investment in real-world evidence has been almost the exclusive domain of large pharma,” Aetion CEO Carolyn Magill said in a statement. “By combining IBM Watson Health’s data source and a best-in-class analytics platform in this bundled offering, innovative mid-market biopharma companies can now benefit from integrating real-world data into drug development and commercialization to help them solve data-driven challenges.”
To read the full press release, click here.
